Elanco Animal Health Inc (ELAT) Stock Analysis
DELISTED 2020
What happened to Elanco Animal Health Inc (ELAT) stock?
Elanco Animal Health Inc (ELAT) no longer trades on public markets. It was delisted in January 2020. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Elanco Animal Health Inc (ELAT) trades at $21.32. Elanco Animal Health Inc. focuses on developing and marketing products for companion and food animals, aiming to improve animal health and welfare. Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for ELAT: ELAT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ELAT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ELAT: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Elanco Animal Health Inc (ELAT) Healthcare & Pipeline Overview
Elanco Animal Health Inc. operates within the animal health sector, providing pharmaceuticals and vaccines for both companion and food animals. With a gross margin of 55.0%, the company faces challenges in profitability, indicated by a negative P/E ratio, while navigating a competitive landscape focused on animal well-being.
What Is the Investment Thesis for ELAT?
Elanco Animal Health Inc. presents a complex investment case. While the company operates in a growing animal health market, its negative P/E ratio of -45.66 and a negative profit margin of -4.9% raise concerns about profitability. A key value driver is the company's strong gross margin of 55.0%, indicating potential for improved profitability through cost management and operational efficiencies. Upcoming growth catalysts include new product launches and expansion into emerging markets. Investors should monitor the company's ability to improve its financial performance and capitalize on growth opportunities in the animal health sector.
Based on FMP financials and quantitative analysis
ELAT Key Highlights
Gross margin of 55.0% indicates strong pricing power and efficient production.
- Negative P/E ratio of -45.66 reflects current unprofitability, requiring careful monitoring.
- Operates in the growing animal health market, driven by increasing pet ownership and demand for animal protein.
- Spun off from Eli Lilly in 2019, allowing for focused management and strategic decision-making.
- Global presence in North America, Europe, Latin America, and Asia-Pacific provides diversification and growth opportunities.
Who Are ELAT's Competitors?
ELAT is benchmarked below against 6 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| ESALY Eisai Co., Ltd. | $61.51 | -2.11% | $17.6B | 57 |
| FPHAX Fidelity Select Pharmaceuticals | $35.95 | -3.00% | $1.29B | 47 |
| AMRT American Mart Corporation | $110.00 | +0.00% | 46 | |
| CORI Corium International, Inc. | $12.68 | +0.00% | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ELAT's Key Strengths?
Global presence and distribution network.
- Diverse product portfolio for companion and food animals.
- Strong brand recognition in the animal health market.
- Focus on innovation and research and development.
What Are ELAT's Weaknesses?
Negative profit margin and P/E ratio.
- Dependence on regulatory approvals for new products.
- Exposure to currency fluctuations.
- Competition from other major animal health companies.
What Could Drive ELAT Stock Higher?
New product launches in the companion animal segment expected in Q3 2026.
- Expansion of distribution network in emerging markets.
- Focus on cost management and operational efficiencies to improve profitability.
What Are the Key Risks for ELAT?
Negative return on equity (-3.6%) — the business is not currently generating profit on shareholder capital.
- Economic downturns could reduce demand for animal health products.
- Changes in regulations and trade policies could impact the company's operations.
- Emergence of new diseases and pests could disrupt the animal health market.
- Competition from other major animal health companies.
What Are the Growth Opportunities for ELAT?
- Growth opportunity 1: Expansion into emerging markets represents a significant growth opportunity for Elanco. As incomes rise in countries such as China and India, demand for animal protein and pet ownership are expected to increase, driving demand for animal health products. Elanco can leverage its global presence and product portfolio to capitalize on this trend, potentially increasing revenue by 10-15% over the next 3-5 years.
- Growth opportunity 2: New product launches and innovation are critical for Elanco's growth. The company invests in research and development to develop new products and improve existing ones. Successful product launches can drive revenue growth and increase market share. Elanco's focus on innovation can lead to a competitive advantage and sustainable growth in the animal health market.
- Growth opportunity 3: Strategic acquisitions and partnerships can expand Elanco's product portfolio and geographic reach. The company has a history of making acquisitions to strengthen its position in the animal health market. Strategic partnerships can provide access to new technologies and markets, driving growth and diversification.
- Growth opportunity 4: Focus on companion animal health represents a significant growth opportunity for Elanco. The increasing pet ownership and humanization of pets are driving demand for companion animal health products. Elanco can capitalize on this trend by developing and marketing innovative products for companion animals, such as flea and tick preventatives, parasiticides, and vaccines.
- Growth opportunity 5: Advancements in precision livestock farming offer opportunities for Elanco to integrate its products with data-driven solutions. This includes developing technologies that monitor animal health in real-time, allowing for proactive interventions and improved animal welfare. This integration can lead to increased efficiency and profitability for livestock producers, driving demand for Elanco's products.
What Are ELAT's Competitive Advantages?
- Strong brand recognition in the animal health market.
- Established relationships with veterinarians and livestock producers.
- Proprietary products and technologies.
- Global distribution network.
What Does ELAT Do?
Elanco Animal Health Inc. is a global animal health company that develops and markets products to improve animal health and welfare. Spun off from Eli Lilly in 2019, Elanco has established itself as a significant player in the animal health industry, focusing on innovation, customer service, and sustainability. The company's portfolio includes a wide range of products for companion animals, such as flea and tick preventatives, parasiticides, and vaccines, as well as products for food animals, including antibiotics, vaccines, and feed additives. Elanco operates globally, with a presence in North America, Europe, Latin America, and Asia-Pacific. The company aims to address the evolving needs of pet owners and livestock producers by providing solutions that enhance animal health, productivity, and well-being. Elanco faces competition from other major animal health companies, but differentiates itself through its focus on innovation and customer relationships.
What Products and Services Does ELAT Offer?
- Develops and markets pharmaceuticals for companion animals.
- Offers vaccines for livestock.
- Provides parasiticides for both companion and food animals.
- Manufactures antibiotics for food animals.
- Creates feed additives to improve animal health and productivity.
- Focuses on improving animal health and welfare globally.
How Does ELAT Make Money?
- Develops and manufactures animal health products.
- Sells products directly to veterinarians and livestock producers.
- Distributes products through wholesalers and retailers.
- Invests in research and development to innovate new products.
What Industry Does ELAT Operate In?
Elanco Animal Health Inc. operates in the global animal health market, which is driven by factors such as increasing pet ownership, rising demand for animal protein, and growing awareness of animal health and welfare. The market is competitive, with major players including Zoetis, Merck Animal Health, and Boehringer Ingelheim Animal Health. Elanco aims to differentiate itself through its focus on innovation, customer service, and sustainability. The animal health market is expected to continue to grow in the coming years, driven by increasing demand for animal products and rising incomes in emerging markets.
Who Are ELAT's Key Customers?
- Veterinarians who prescribe and administer animal health products.
- Livestock producers who use products to improve animal health and productivity.
- Pet owners who purchase products for their companion animals.
- Distributors and retailers who sell animal health products.
Company Profile
Elanco Animal Health Inc operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. ELAT has traded publicly since 2020.
Key Financial Metrics
Return on equity for Elanco Animal Health Inc stands at -3.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.3%, the inverse of the P/E and a quick read on earnings relative to price.
ELAT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Elanco's recent insider buying suggests those in the know see long-term value, a classic 'follow the smart money' signal. Think of it like Buffett adding to his Apple stake – confidence inspiring.
- Community chatter highlights Elanco's strong relationships with veterinarians, a key factor for repeat business and brand loyalty. It's like having a built-in sales force.
- Positive sentiment revolves around Elanco's innovative product pipeline, with hopes for new treatments boosting revenue. This is similar to the anticipation surrounding new drugs for biotech firms.
- The market perceives Elanco as a stable player in a growing industry, benefiting from increased pet ownership and focus on animal health. This is akin to the steady growth seen in consumer staples.
Bear Case
- Recent community sentiment expresses concern over potential regulatory hurdles for new Elanco products, creating uncertainty. This is similar to the challenges faced by pharmaceutical companies awaiting FDA approval.
- Bearish views focus on increased competition in the animal health market, potentially squeezing margins. Think of the airline industry, where intense competition can hurt profitability.
- Insider selling, though less prominent than buying, raises eyebrows among some investors, creating a sense of caution. It's like seeing executives selling shares before a company announces bad news.
- Market perception suggests Elanco may face challenges integrating recent acquisitions, potentially leading to operational inefficiencies. This is akin to the integration struggles seen in some large tech mergers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ELAT Latest News
No recent news available for ELAT.
Leadership: None
CEO title
Unknown
Track Record: Unknown
ELAT Healthcare Stock FAQ
What happened to Elanco Animal Health Inc (ELAT) stock?
Elanco Animal Health Inc (ELAT) no longer trades on public markets. It was delisted in January 2020. The figures below are historical and are not a current quote.
Can I still buy ELAT shares?
No. ELAT stopped trading on public markets in January 2020, so the shares are not available through a broker. Anything you see quoted for ELAT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ELAT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Elanco Animal Health Inc. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Elanco Animal Health Inc do?
Elanco Animal Health Inc. is a global animal health company that develops, manufactures, and markets a wide range of products for both companion and food animals. These products include pharmaceuticals, vaccines, parasiticides, and feed additives, all aimed at improving animal health, welfare, and productivity.
What do analysts say about ELAT stock?
Analyst consensus on Elanco Animal Health Inc. is currently mixed, reflecting the company's challenges in achieving profitability despite its strong gross margin. Key valuation metrics, such as the negative P/E ratio, indicate potential concerns about earnings. Growth considerations include the company's ability to capitalize on opportunities in emerging markets and through new product launches. Investors should carefully monitor Elanco's financial performance and strategic initiatives to assess its long-term growth potential.
What are the main risks for ELAT?
Elanco Animal Health Inc. faces several key risks, including economic downturns that could reduce demand for animal health products, changes in regulations and trade policies that could impact its operations, and the emergence of new diseases and pests that could disrupt the animal health market. Increased competition from generic products and other major animal health companies also poses a threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide further insights.